Tuesday, April 18, 2017 7:02:09 AM
"We have not generated significant revenue during the years ended December 31, 2016 and 2015. We have operating expenses related to general and administrative expenses and research and development expenses. During the year ended December 31, 2016, we incurred a net loss of $2,287,329 due principally to general and administrative expenses of $ 2,006,216 and research and development expenses of $141,858, adjusted for convertible loans of $180,340, exchange differences on principal of long-term loan of $16,972, other finance income of $8,057 compared to a net loss of $1,654,988 due to general and administrative expenses of $1,380,029, research and development expenses of $271,394, and financing expenses of $3,565 in the prior year."
A discussion on this would be nice
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM